The $41 million deficit was despite improved revenues for the three months ending Sept. 30, 2022, of $1.78 billion compared to $1.63 billion in the same period last year.
While salary costs climbed 14 percent to $830 million for the quarter compared to the same period in 2021, materials and supply costs rose almost 10 percent to total $676 million. Investment losses also contributed significantly to quarterly performance with a net loss totaling $75 million related to future capital and operating needs.
Cedars-Sinai last month joined a $31 million funding round for Vita Therapeutics, a company that uses genetics to develop new cellular therapies to treat muscular dystrophy and cancer.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.